1-Methyl-5-aethyl-uracil | 19030-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-Methyl-5-aethyl-uracil
• 英文别名: 5-ethyl-1-methyl-1H-pyrimidine-2,4-dione；5-Ethyl-1-methylpyrimidine-2,4-dione
• CAS: 19030-68-3
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: OMFJIQMVWTWWOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、X和Z如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病为II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267688A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中定义。该发明还包括一种预防、治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是2型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用式(I)的至少一种化合物的治疗有效量来抑制CCR2活性的方法。
• 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100144695A1

  公开（公告）日：2010-06-10

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

  本发明涉及式（I）的化合物。其中：R1、R2、R3和R4如规范中所定义。该发明还涉及包含式（I）化合物的药物组合物，以及通过给予式（I）化合物来预防、治疗或改善CCR2介导的综合症、疾病或疾病的方法，例如II型糖尿病、肥胖或哮喘。
• [EN] NUCLEOTIDE CLEAVABLE LINKERS WITH RIGID SPACERS AND USES THEREOF<br/>[FR] LIEURS CLIVABLES DE NUCLÉOTIDES À ESPACEURS RIGIDES ET LEURS UTILISATIONS
  申请人：SINGULAR GENOMICS SYSTEMS INC

  公开号：WO2021226327A1

  公开（公告）日：2021-11-11

  Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.

  本文披露了一些化合物、组合物及其使用方法，用于对核酸进行测序。
• COMPOUNDS AND METHODS OF MAKING COMPOUNDS
  申请人：Namavari Mohammad

  公开号：US20110059014A1

  公开（公告）日：2011-03-10

  Embodiments of the present disclosure provide for compounds and methods of making compounds such as those shown in FIGS. 1.1 A and 1.1 B having formula 2, 3, 4, 5, 11, and 12 and formula 2′, 4′, and 11′, as well as uses for the compounds for imaging, and the like.

  本公开说明的实施例提供了化合物及其制备方法，例如图1.1A和1.1B中所示的具有公式2、3、4、5、11和12以及公式2'、4'和11'的化合物，以及化合物用于成像等用途。